Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
News
- Mar 21
Mike Grey appointed Executive Chair of Theolytics’ Board of Directors
- Nov 28, 2023
Theolytics presents data at ESMO on its lead program being developed for Ovarian Cancer
- Jun 9, 2023
Theolytics presents data on THEO-260 and THEO-310 at ASCO and EHA
- Oct 6, 2022
Theolytics presents CAF-targeting therapy for stromal rich tumours, and strengthens leadership team
- May 31, 2022
Theolytics' £1M project with InnovateUK to develop a novel therapy for multiple myeloma patients
- Jul 8, 2021
Theolytics expands Series A financing and welcomes M Ventures as a new investor
- Jul 1, 2021
Theolytics is taking part in the BIA Research Relay 2021
- Nov 6, 2020
Theolytics awarded Innovate UK boost to help combat ovarian cancer
- Sep 21, 2020
Theolytics announces appointment of Immatics’ Carsten Reinhardt to its Board of Directors
- Jan 7, 2020
Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures